Medication for Diarrhea

Marion Debus

Last update: 12.06.2019

  • For diarrhea:
    Birkenkohle comp. caps. WELEDA (also available as Carbo Betulae comp. tabs. WELEDA), 2 per bowel movement, or 3 x daily up to hourly
    or
    Bolus alba comp. powder WALA, 1–3 tsp. daily, each in 200 ml liquid 

  • For diarrhea and vomiting:
    Bolus alba comp. powder WALA, 1 saltsp. (~1/4 tsp.) hourly 

  • In situations of damage to the small intestine mucosa caused by chemotherapy or radiation therapy:
    Digestodoron® WELEDA, chew 2 tabs. at the beginning of each meal 3x/d, or 15 drops 4x/d
    or
    in addition, to stimulate renal and hepatic detoxification function while undergoing chemotherapy:
    Aquilinum comp. pillules WALA, 7–10 pillules 3x/d or 1 amp. per os 1x/d

  • In case of mucous membrane damage as a result of radiation therapy:
    Stibium arsenicosum D6 trit. WELEDA, 1 saltsp. (~1/4 tsp.) 3x/d
    or,
    with particularly mucousy diarrhea:
    Geum urbanum D1 WELEDA, 10 drops 3–6x/d

  • For Enterocolitis with mucousy diarrhea and high fluid loss:
    Quartz powder 50% WELEDA, take ¼ tsp. with a little liquid 5x/d

  • For unrelenting diarrhea in GvHD after bone marrow transplantation:
    Luvos Healing Earth gastro balance (also available as Luvos-Heilerde magenfein), 1 tsp. 3x/d

  • Diarrhea during radiation of the rectum as part of (neo)adjuvant chemoradiotherapy for rectal cancer. In the last third of therapy, local irritations and diarrhea can usually be expected.
    Local: Mercurialis ointment WALA and Mercurialis comp. supp. WALA 
    or,
    Bolus alba comp. powder WALA
    Stibium arsenicosum D6 trit. WELEDA, 1 saltsp. (~1/4 tsp.) 3x/d
    Geum urbanum D1 WELEDA, 10 drops 3–6x/d

Research news

Case series: Topical application of Viscum album extract in keratinocyte carcinomas shows remissions 
A retrospective case series examined the safety and clinical effects of topical application of 10% lipophilic Viscum album extract (VALE) in individual cases of cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC) and actinic keratosis (AK). The study population consisted of 55 patients with 74 skin lesions. Risk factors, concomitant therapies and diseases, adverse drug reactions to VALE and other relevant information were documented. As a result, the clinical response rate was 78% for cSCC, 70% for BCC and 71% for AK. The complete remission rates for individual lesions were 56% for cSCC, 35% for BCC and 15% for AK. Overall, the results suggest that VALE is a safe and tolerable extract, and complete and partial remissions of ceratinocyte carcinomas were observed with its use. The article is published in Complementary Medicine Research
https://doi.org/10.1159/000537979.


Further information on Anthroposophic Medicine